Annual CFO
-$19.81 M
+$5.06 M+20.34%
December 1, 2023
Summary
- As of February 20, 2025, RNTX annual cash flow from operations is -$19.81 million, with the most recent change of +$5.06 million (+20.34%) on December 1, 2023.
- During the last 3 years, RNTX annual CFO has risen by +$668.00 thousand (+3.26%).
Performance
RNTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFO
-$3.82 M
+$4.57 M+54.48%
September 1, 2024
Summary
- As of February 20, 2025, RNTX quarterly cash flow from operations is -$3.82 million, with the most recent change of +$4.57 million (+54.48%) on September 1, 2024.
- Over the past year, RNTX quarterly CFO has increased by +$1.45 million (+27.55%).
Performance
RNTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
-$27.87 M
-$2.18 M-8.48%
September 1, 2024
Summary
- As of February 20, 2025, RNTX TTM cash flow from operations is -$27.87 million, with the most recent change of -$2.18 million (-8.48%) on September 1, 2024.
- Over the past year, RNTX TTM CFO has dropped by -$7.45 million (-36.50%).
Performance
RNTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
RNTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +20.3% | +27.6% | -36.5% |
| 3 y3 years | +3.3% | +18.1% | -28.3% |
| 5 y5 years | +29.1% | +45.3% | -13.1% |
RNTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +25.5% | +132.9% | +172.1% | +101.6% | at low |
| 5 y | 5-year | at high | +33.7% | +132.9% | +172.1% | +101.6% | at low |
| alltime | all time | +69.2% | +41.0% | +132.9% | +172.1% | +643.6% | +2.3% |
Rein Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3.82 M(-54.5%) | -$27.87 M(+8.5%) |
| Jun 2024 | - | -$8.39 M(+59.2%) | -$25.69 M(+25.8%) |
| Mar 2024 | - | -$5.27 M(-49.3%) | -$20.42 M(+3.1%) |
| Dec 2023 | -$19.81 M(-20.3%) | -$10.39 M(+533.6%) | -$19.81 M(+43.3%) |
| Sep 2023 | - | -$1.64 M(-47.4%) | -$13.83 M(-27.8%) |
| Jun 2023 | - | -$3.12 M(-33.1%) | -$19.16 M(-11.8%) |
| Mar 2023 | - | -$4.66 M(+5.7%) | -$21.73 M(-12.6%) |
| Dec 2022 | -$24.86 M(+4.7%) | -$4.41 M(-36.8%) | -$24.86 M(-6.9%) |
| Sep 2022 | - | -$6.97 M(+22.6%) | -$26.71 M(-1.1%) |
| Jun 2022 | - | -$5.68 M(-27.1%) | -$27.00 M(+7.7%) |
| Mar 2022 | - | -$7.80 M(+24.7%) | -$25.08 M(+5.6%) |
| Dec 2021 | -$23.75 M(+16.0%) | -$6.25 M(-13.8%) | -$23.75 M(+7.1%) |
| Sep 2021 | - | -$7.26 M(+92.9%) | -$22.19 M(+11.1%) |
| Jun 2021 | - | -$3.76 M(-41.9%) | -$19.97 M(-6.2%) |
| Mar 2021 | - | -$6.48 M(+38.1%) | -$21.28 M(+3.9%) |
| Dec 2020 | -$20.48 M | -$4.69 M(-7.0%) | -$20.48 M(-7.3%) |
| Sep 2020 | - | -$5.04 M(-0.6%) | -$22.09 M(-8.0%) |
| Jun 2020 | - | -$5.07 M(-10.6%) | -$24.02 M(-2.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$5.67 M(-10.0%) | -$24.64 M(-6.9%) |
| Dec 2019 | -$26.47 M(-5.2%) | -$6.30 M(-9.6%) | -$26.47 M(-1.3%) |
| Sep 2019 | - | -$6.98 M(+22.6%) | -$26.83 M(+0.4%) |
| Jun 2019 | - | -$5.69 M(-24.1%) | -$26.73 M(-6.2%) |
| Mar 2019 | - | -$7.50 M(+12.6%) | -$28.50 M(+2.0%) |
| Dec 2018 | -$27.93 M(+36.0%) | -$6.66 M(-3.1%) | -$27.93 M(+3.0%) |
| Sep 2018 | - | -$6.88 M(-7.8%) | -$27.10 M(+6.4%) |
| Jun 2018 | - | -$7.46 M(+7.6%) | -$25.46 M(+18.4%) |
| Mar 2018 | - | -$6.93 M(+18.7%) | -$21.51 M(+4.8%) |
| Dec 2017 | -$20.53 M(+36.7%) | -$5.84 M(+11.5%) | -$20.53 M(+8.5%) |
| Sep 2017 | - | -$5.24 M(+49.4%) | -$18.93 M(+7.4%) |
| Jun 2017 | - | -$3.50 M(-41.1%) | -$17.62 M(+2.3%) |
| Mar 2017 | - | -$5.95 M(+40.6%) | -$17.22 M(+14.7%) |
| Dec 2016 | -$15.01 M(+28.2%) | -$4.23 M(+7.8%) | -$15.01 M(+39.3%) |
| Sep 2016 | - | -$3.93 M(+26.4%) | -$10.78 M(+57.3%) |
| Jun 2016 | - | -$3.11 M(-17.1%) | -$6.86 M(+82.9%) |
| Mar 2016 | - | -$3.75 M | -$3.75 M |
| Dec 2015 | -$11.71 M | - | - |
FAQ
- What is Rein Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Rein Therapeutics?
- What is Rein Therapeutics annual CFO year-on-year change?
- What is Rein Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Rein Therapeutics?
- What is Rein Therapeutics quarterly CFO year-on-year change?
- What is Rein Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Rein Therapeutics?
- What is Rein Therapeutics TTM CFO year-on-year change?
What is Rein Therapeutics annual cash flow from operations?
The current annual CFO of RNTX is -$19.81 M
What is the all time high annual CFO for Rein Therapeutics?
Rein Therapeutics all-time high annual cash flow from operations is -$11.71 M
What is Rein Therapeutics annual CFO year-on-year change?
Over the past year, RNTX annual cash flow from operations has changed by +$5.06 M (+20.34%)
What is Rein Therapeutics quarterly cash flow from operations?
The current quarterly CFO of RNTX is -$3.82 M
What is the all time high quarterly CFO for Rein Therapeutics?
Rein Therapeutics all-time high quarterly cash flow from operations is -$1.64 M
What is Rein Therapeutics quarterly CFO year-on-year change?
Over the past year, RNTX quarterly cash flow from operations has changed by +$1.45 M (+27.55%)
What is Rein Therapeutics TTM cash flow from operations?
The current TTM CFO of RNTX is -$27.87 M
What is the all time high TTM CFO for Rein Therapeutics?
Rein Therapeutics all-time high TTM cash flow from operations is -$3.75 M
What is Rein Therapeutics TTM CFO year-on-year change?
Over the past year, RNTX TTM cash flow from operations has changed by -$7.45 M (-36.50%)